DEVELOPMENT OF PERORAL HYPOLIPIDEMIC FORMULATION BASED ON SULFATED ARABINOGALACTAN IN THE FORM OF POTASSIUM SALT

An original heparinoid, sulfated arabinogalactan in the form of potassium salt, possessing anticoagulant and hypolipidemic activities, has been developed at  the A.E. Favorsky Irkutsk Institute of Chemistry Siberian Branch of the Russian Academy of Sciences.

The aim was to develop solid peroral dose forms (capsules and film-coated tablets) for the prevention and treatment of atherosclerotic lesion of blood vessels on the basis of potassium salt of sulfated arabinogalactan which would be suitable for further clinical trials of these forms.

Materials and methods. The following materials were used in the work: sulfated arabinogalactan in the form of potassium salt, obtained at the A.E. Favorsky Irkutsk Institute of Chemistry Siberian Branch of the Russian Academy of Sciences; Ludipress®; AEROSIL® 200 Pharma; calcium stearate; Aquacoat ECD. The powder mixtures were briquetted followed by tableting and application of the finished film coating Aquacoat ECD, and encapsulation in hard gelatin capsules.

Results. Composition and technological characteristics of capsules and film-coated tablets were determined using physico-chemical and technological properties of sulfated arabinogalactan in the form of potassium salt. Technological parameters and quality indicators were determined for the solid pharmaceutical dose forms in accordance with the requirements of the State Pharmacopoeia of the Russian Federation of the XIV^th edition.

Conclusion. The optimum compositions and technology for the preparation of capsules and film-coated tablets based on potassium salt of sulfated arabinogalactan for the prevention and treatment of atherosclerotic lesion of blood vessels, were developed. The data obtained were used for the regulatory documentation design.

1. Kumar N, Bentolila A, Domb AJ. Structure and biological activity of heparinoid. Mini Reviews in Medicinal Chemistry. 2005; 5 (5): 441-7. https://doi.org/10.2174/1389557053765538.

2. Borai IH, Ezz MK, Rizk MZ, El-Sherbiny M, Matloub AA, Aly HF, Farrag AR, Fouad GI. Hypolipidemic and anti-atherogenic effect of sulphated polysaccharides from the green alga Ulva fasciata. Int J Pharm Sci Rev Res. 2015; 31 (1): 1-12.

3. Park J, Yeom M, Hahm D-H. Fucoidan improves serum lipid levels and atherosclerosis through hepatic SREBP-2-mediated regulation. J Pharmacol Sci. 2016; 131 (2): 84-92. https://doi.org/10.1016/j.jphs.2016. 03.007.

4. Rizk MZ. The anti-hypercholesterolemic effect of ulvan polysaccharide extracted from the green alga Ulva fasciata on aged hypercholesterolemic rats. Asian J Pharm Clin Res. 2016; 9 (3): 165-76.

5. Yokota T, Nomura K, Nagashima M, Kamimura N. Fucoidan alleviates high-fat diet-induced dyslipidemia and atherosclerosis in ApoE(shl) mice deficient in apolipoprotein E expression. J Nutr Biochem. 2016; 32: 46-54. https://doi.org/10.1016/j.jnutbio.2016.01.011.

6. Deniaud-Bouët E, Hardouin K, Potin P, Kloareg B, Hervé C. A review about brown algal cell walls and fucose-containing sulfated polysaccharides: cell wall context, biomedical properties and key research challenges. Carbohydr Polym. 2017; 175: 395-408. https://doi.org/10.1016/j.carbpol.2017.07.082.

7. Li W, Wang K, Jiang N, Liu X, Wan M, Chang X, Liu D, Qi H, Liu Sh. Antioxidant and antihyperlipidemic activities of purified polysaccharides from Ulva pertusa. J Appl Phycol. 2018; 30: 2619-27. https://doi.org/10.1007/s10811-018-1475-5.

8. Yulis K, Hakim B, Rosidah R. Effect of sodium alginate on prevention of hypercholesterolemia and atherosclerosis in rats. Asian J Pharm Clin Res. 2018; 11 (6): 242-7. https://doi.org/10.22159/ajpcr.2018.v11i6.24768.

9. Barkagan ZS, Momot AP. Osnovy diagnostiki narushenii gemostaza. [Foundations of diagnostics of homeostasis disturbance]. Moscow: Nyudiamed AO. 2000: 42-56. Russian

10. Masola V, Zaza G, Onisto M, Lupo A, Gambaro G. Glycosaminoglycans, proteoglycans and sulodexide and the endothelium: biological roles and pharmacological effects. Int Angiol. 2014; 33 (3): 243-54.

11. Xin M, Ren L, Sun Ya, Li H-h. Guan H.-Sh, He X-X, Li Ch-X. Anticoagulant and antithrombotic activities of low-molecular-weight propylene glycol alginate sodium sulfate (PSS). Eur J Med Chem. 2016; 114: 33-40. https://doi.org/10.1016/j.ejmech.2016.02.063.

12. Patil NP, Le V, Sligar AD, Mei L, Chavarria D. Yang EY, Baker AB. Algal polysaccharides as therapeutic agents for atherosclerosis. Front Cardiovasc Med. 2018; 5: 1-18. https://doi.org/10.3389/fcvm.2018.00153.

13. Braga WF, Aguilar EC, Alvarez-Leite JaI. Fucoidans as a potential nutraceutical in combating atherosclerotic cardiovascular diseases. Biomed J Sci & Tech Res. 2019; 21 (Issue 3): 15953-8. https://doi.org/10.26717/BJSTR.2019.21.003616.

14. Coccheri S, Mannello F. Development and use of sulodexide in vascular diseases: implications for treatment. Drug Des Devel Ther. 2014; 8: 49-65. https://doi.org/10.2147/DDDT.S6762.

15. Hoppensteadt DA, Fareed J. Pharmacological profile of sulodexide. Int Angiol. 2014; 33 (Issue 3): 229-35.

16. Condorelli M, Chiariello M, Dagianti A, Penco M, Dalla Volta S, Pengo V, Schivazappa L, Mattioli G, Mattioli AV, Brusoni B, Trotta E, Bingamini A. IPO-V2: A prospective, multicenter, randomized, comparative clinical investigation of the effects of sulodexide in preventing cardiovascular accidents in the first year after acute myocardial infarction. J Am Coll Cardiol. 1994; 23 (Issue 1): 27-34. https://doi.org/10.1016/0735-1097(94)90498-7.

17. Coccheri S, Scondotto G, Agnelli G, Palazzini E, Zamboni V. Sulodexide in the treatment of intermittent claudication. Results of a randomized, double-blind, multicentre, placebo-controlled study. Eur Heart J. 2002; 23 (13): 1057-65. https://doi.org/10.1053/euhj.2001.3033.

18. Chupin AV, Katorkin SE, Katelnitsky II, Katelnitskaya OV, Prostov II, Petrikov AS, Koshevoi AP, Lyudkova LF. Sulodexide in the treatment of chronic venous insufficiency: results of the All-Russian multicenter ACVEDUCT program. Adv Ther. 2020; 37 (Issue 5): 2071-82. https://doi.org/10.1007/s12325-020-01270-9.

19. Kostyro YaA, Kovalskaya GN, Silizertseva OA, Ilyina OP. Eksperimental’naya farmakokinetika sul’fatirovannogo arabinogalaktana pri razlichnyh putyah vvedeniya. [Experimental pharmacokinetics of sulfated arabinogalactan for various routes of administration]. Farmaciya. = Pharmacy. 2008; 1: 45-6. Russian

20. Kostyro YaA, Stankevich VK, Trofimov BA, inventors; Federal’noe gosudarstvennoe bjudzhetnoe uchrezhdenie nauki Irkutskij institut khimii im. A.E. Favorskogo Sibirskogo otdelenija Rossijskoj akademii nauk [Federal State Budget Institution for Science “A.E. Favorsky Irkutsk Institute of Chemistry Siberian Branch of the Russian Academy of Sciences”], assignee. Sposob polucheniya sul’fatirovannyh proizvodnyh arabinogalaktana, obladayushchih antikoagulyantnoj i gipolipidemicheskoj aktivnost’yu [Method of obtaining sulfated derivatives of arabinogalactan with anticoagulant and hypolipidemic activity]. Russian Federation patent RU 2532915. 2014 Nov 20. Russian

21. Kostyro YaA, Stankevich VK. New approach to the synthesis of an active substance of Agsular® pharmaceutical for the prevention and treatment of atherosclerosis. Russ Chem Bull. (Int Ed) 2015; 64 (Issue 7): 1576-80. https://doi.org/10.1007/s11172-015-1044-x.

22. Kostyro YaA, Kolbasov SE. Issledovanie bezopasnosti substancii Agsular®. [Investigation of the safety of the Agsular® substance]. Eksperimental’naya i klinicheskaya farmakologiya. = Experimental and clinical pharmacology. 2017; 80 (S6): 17. (in Russian)

23. Kostyro YaA, Kostyro VV. Issledovanie farmakologicheskoj aktivnosti substancii Agsular®. [Study of the pharmacological activity of the Agsular® substance]. Eksperimental’naya i klinicheskaya farmakologiya. [Experimental and clinical pharmacology]. 2018; 81 (S): 124. https://doi.org/10.30906/0869-2092-2018-81-5s-1-306. Russian

24. Menshutina NV, Mishina YuV, Alves SV. Innovacionnye tekhnologii i oborudovanie farmacevticheskogo proizvodstva. [Innovative technologies and equipment for pharmaceutical production]. Moscow: BINOM; 2012: 328. Russian

25. Alqahtani MS, Kazi M, Alsenaidy MA, Ahmad MZ. Advances in Oral Drug Delivery. Front Pharmacol. 2021; 12: 1-21. https://doi.org/10.3389/fphar.2021.618411.

26. Walter MB, Tyutenkov OL, Philippin NA. Postadijnyj kontrol’ v proizvodstve tabletok. [Step-by-step control in the production of tablets]. Moscow: Medicine. 1982: 208. Russian

27. Hausner HH. Friction conditions in a mass of metal powder. Int J Powder Metall. 1967; 3: 7-13.

28. Carr RL. Evaluating flow properties of solids. Chem Eng. 1965; 72: 163-8.

29. Iqubal MK, Singh PK, Shuaib M, Iqubal A, Singh M. Recent advances in direct compression technique for pharmaceutical tablet formulation. Int J Pharm Res & Devel. 2014; 6 (Issue 1): 49-57.

30. Basov NI, Lyubartovich VA, Lyubartovich SA. Kontrol’ kachestva polimernyh materialov. [Quality control of polymer materials]. Leningrad: Chemistry. 1990: 112. Russian

31. Makhkamov SM. Osnovy tabletochnogo proizvodstva. [Basics of tablet production]. Tashkent: FAN. 2004: 148. Russian

32. Cain J. An alternative technique for determining ANSI/CEMA standard 550 flowability ratings for granular materials. Powder Hand Proc. 2002; 14 (Issue 3): 218-20.

33. Ogata K. A review: recent progress on evaluation of flowability and floodability of powder. KONA Powder and Particle Journal. 2019; 36: 33-49. https://doi.org/10.14356/kona.2019002.

34. Kostyro YaA, Kovalskaya GN, Sukhoterina NV, Turetskova VF. Tabletirovannaya lekarstvennaya forma preparata AGSK. [Tablet dosage form of AGSK]. In: Chuchalin AG, Belousov YuB, editors. Chelovek i lekarstvo. [Man and Medicine]. XV Russian National Congress; 2008 Apr 14-18; Moscow, Russian Federation. Moscow: RITS CJSC “Man and Medicine”. 2008: 643 p. Russian

35. Schmidt PC, Rubensdörfer CJW. Evaluation of Ludipress as a “Multipurpose Excipeent” for direct compression: Part I: Powder characteristics and tableting properties. Drug Development and Industrial Pharmacy. 1994; 20 (Issue 18): 2899-25. https://doi.org/10.3109/03639049409042687.

36. Sridevi G, Korangi V, Latha SM. Review on a novel approach in recent advances of granulation techniques and technologies. Research J Pharm And Tech. 2017; 10 (Issue 2): 607-17. https://doi.org/10.5958/0974-360X.2017.00119.6.

37. Patil LP, Rawal VP. Review article on granulation process with novel technology: an overview. Indian Journal of Applied Research. 2017; 7 (Issue 6): 90-3. https://doi.org/10.36106/ijar.

38. Aulton ME. Pharmaceutics: The Science of Dosage Form Design. Edinburgh: Churchill Livingstone. 2004: 679 p.

39. Mogilyuk V. Funkcional’nye plenochnye pokrytiya i prakticheskie aspekty ih primeneniya. [Functional film coatings and practical aspects of their application]. Farmacevticheskaya otrasl’ = Pharmaceutical industry. 2016; 1: 52-65.

40. Wasilewska K, Winnicka K. Ethylcellulose - a pharmaceutical excipient with multidirectional application in drug dosage forms development. Materials. 2019;12: 1-21. https://doi.org/10.3390/ma12203386.

41. Sepulveda E, Kildsig DO, Ghaly ES. Relationship between internal phase volume and emulsion stability: the cetyl alcohol / stearyl alcohol system. Pharm Devel Tech. 2003; 8 (Issue 3): 263-75. https://doi.org/10.1081/PDT-120022155.

42. Porter SC. Preventing film coating problems through design. Pharmaceutical Technology. 2016; 28 (Issue 2): 43-6.

43. Himaja V, Sai KO, Karthikeyan R, Srinivasa BP. A comprehensive review on tablet coating. Austin Pharmacol Pharm. 2016; 1 (Issue 1): 1-8.

44. Elder D. Design, formulation and manufacture of film-coated drug products. Eur Pharm Rev. 2017; 22 (Issue 5): 37-40.

45. Zaid AN. A comprehensive review on pharmaceutical film coating: past, present, and future. Drug Design, Development and Therapy. 2020; 14: 4613-23. https://doi.org/10.2147/DDDT.S277439.

46. Amelian A, Winnicka K. Polymers in pharmaceutical taste masking applications. Polimery. 2017; 62 (6): 419-27. https://doi.org/10.14314/polimery.2017.419.